NIKI Niki BioSolutions, Inc.
Measuring & Controlling Devices, NEC · Nasdaq · SEC CIK 1734005 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-66.7%
TTM net income YoY71.2%
TTM EPS YoY77.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin2.4%
Operating margin—
Net margin-654.8%
FCF margin-1,791.3%
EBITDA margin—
Returns
ROE-13.9%
ROA-13.6%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets25.5%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.73x
Accruals ratio23.6%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $431,378 | $1.30M | $1.54M |
| Cost of revenue | — | — | $420,812 | $1.22M | $1.46M |
| Gross profit | — | — | $10,566 | $80,065 | $81,854 |
| R&D expense | $352,879 | $2.20M | $5.20M | $9.22M | $10.87M |
| SG&A expense | $573,059 | $669,486 | $1.93M | $5.22M | $5.41M |
| Pretax income | -$1.38M | -$4.16M | -$4.34M | — | — |
| Net income | -$1.36M | -$4.27M | -$2.82M | -$9.80M | -$25.05M |
| EPS (basic) | -0.19 | -0.78 | -0.62 | -2.75 | -7.15 |
| EPS (diluted) | -0.19 | -0.78 | -0.62 | -2.75 | -7.15 |
| Weighted avg. shares (diluted) | 7.35M | 5.45M | 4.52M | 3.57M | 3.50M |
| Balance sheet | |||||
| Cash & equivalents | $3.45M | $874,238 | $2.01M | $5.01M | $8.26M |
| Short-term investments | — | — | — | $102,481 | $236,615 |
| Receivables | — | — | $47,709 | $174,426 | $78,722 |
| Inventory | — | — | — | $27,722 | $35,775 |
| Current assets | $3.59M | $959,554 | $2.48M | $7.07M | $12.69M |
| PP&E, net | — | — | $1.66M | $2.83M | $3.73M |
| Intangibles | — | — | $147,347 | $752,705 | $880,256 |
| Total assets | $18.69M | $16.13M | $20.64M | $20.87M | $21.91M |
| Current liabilities | $4.59M | $4.34M | $2.10M | $12.50M | $4.38M |
| Long-term debt | — | — | — | $129,847 | $296,225 |
| Total debt | — | — | — | $129,847 | $296,225 |
| Total liabilities | $4.90M | $4.35M | $5.26M | $13.03M | $4.40M |
| Shareholders' equity | $23.12M | $21.13M | $24.85M | $15.71M | $23.61M |
| Net debt | — | — | — | -$4.88M | -$7.97M |
| Cash flow statement | |||||
| Operating cash flow | -$1.84M | -$1.19M | -$7.72M | -$12.32M | -$14.65M |
| Capital expenditure | — | — | $3,015 | $186,916 | $131,750 |
| Free cash flow | — | — | -$7.73M | -$12.51M | -$14.78M |
| Investing cash flow | — | $58,621 | $624,767 | $2.44M | $16.51M |
| Financing cash flow | $4.42M | — | $4.09M | $6.63M | $2.78M |
| Depreciation & amortization | — | $255,046 | $1.13M | $1.21M | $1.19M |
| Stock-based compensation | — | — | $1.27M | $1.65M | $1.68M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.